Pfizer Inc.

NYSE:PFE   3:59:59 PM EDT
44.10
-0.47 (-1.06%)
4:08:38 PM EDT: $44.07 -0.03 (-0.07%)
Products, Regulatory

Pfizer Announces Positive Top-Line Results From Phase 3 Trial Of Pentavalent Meningococcal Vaccine Candidate (Menabcwy) In Adolescents

Published: 09/15/2022 10:54 GMT
Pfizer Inc. (PFE) - Pfizer Announces Positive Top-line Results From Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (menabcwy) in Adolescents.
Pfizer Inc - Plans to Submit an Application for Approval to U.S. Food and Drug Administration in Q4 of 2022.
Pfizer Inc - Phase 3 Trial Demonstrates That Investigational Pentavalent Meningococcal Vaccine (menabcwy) Was Well-tolerated.